0000899243-20-017492.txt : 20200623 0000899243-20-017492.hdr.sgml : 20200623 20200623171935 ACCESSION NUMBER: 0000899243-20-017492 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200619 FILED AS OF DATE: 20200623 DATE AS OF CHANGE: 20200623 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Maeusli Heinz Christoph CENTRAL INDEX KEY: 0001788919 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36569 FILM NUMBER: 20983147 MAIL ADDRESS: STREET 1: SCHUETZENWEG 3 CITY: ENGELBURG STATE: V8 ZIP: 9032 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lantheus Holdings, Inc. CENTRAL INDEX KEY: 0001521036 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 352318913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 BUSINESS PHONE: 978 671-8001 MAIL ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 FORMER COMPANY: FORMER CONFORMED NAME: Lantheus MI Holdings, Inc. DATE OF NAME CHANGE: 20110517 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-19 0 0001521036 Lantheus Holdings, Inc. LNTH 0001788919 Maeusli Heinz Christoph C/O LANTHEUS HOLDINGS, INC. 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 1 0 0 0 Common stock 2020-06-19 4 A 0 5981 0.00 A 5981 D Non-Qualified Stock Option (Right to Buy) 16.17 2020-06-19 4 A 0 17481 A 2020-06-19 2029-12-13 Common stock 17481 17481 D Received in exchange for a non-qualified stock option to acquire 56,393 shares of Progenics Pharmaceuticals, Inc. ("Progenics") for $5.01 per share, in connection with the merger of Progenics pursuant to the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 20, 2020, by and among Lantheus Holdings, Inc. (the "Company"), Plato Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"), and Progenics, pursuant to which Merger Sub merged with and into Progenics, with Progenics surviving as a wholly owned subsidiary of the Company (the "Merger"). /s/ Daniel Niedzwiecki, attorney-in-fact 2020-06-23